SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Key Highlights
- ➤SAB BIO (SABS) to present encore Phase 1 SAB-142 data at CRC 2026
- ➤SAB-142 presentations will feature available safety and efficacy data
- ➤SAB-142 is being evaluated in registrational Phase 2b SAFEGUARD trial
- ➤SAFEGUARD evaluates SAB-142 in newly diagnosed Stage 3 autoimmune T1D patients
Expert Statements
Alexandra Kropotova, Chief Medical Officer of SAB BIO
“We are proud to sponsor and participate in the inaugural Breakthrough T1D Clinical & Research Congress, an important forum bringing together researchers, clinicians, industry leaders, and advocates focused on changing the future of type 1 diabetes”
Alexandra Kropotova, Chief Medical Officer of SAB BIO
“Our presentations will feature available safety and efficacy data for SAB-142 and provide information on the SAFEGUARD and PRISE-hATG studies evaluating SAB-142 as a potential immunotherapy across the T1D disease continuum.”
Alexandra Kropotova, Chief Medical Officer of SAB BIO
“Our collaboration with Breakthrough T1D reflects a shared commitment to advancing innovative approaches that move beyond exogenous insulin administration and toward preserving organic endogenous insulin production.”
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.
“We are proud to sponsor and participate in the inaugural Breakthrough T1D Clinical & Research Congress, an important forum bringing together researchers, clinicians, industry leaders, and advocates focused on changing the future of type 1 diabetes,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “Our presentations will feature available safety and efficacy data for SAB-142 and provide information on the SAFEGUARD and PRISE-hATG studies evaluating SAB-142 as a potential immunotherapy across the T1D disease continuum. Our collaboration with Breakthrough T1D reflects a shared commitment to advancing innovative approaches that move beyond exogenous insulin administration and toward preserving organic endogenous insulin production.”
Get started
Create a free account to read the full story.